Processa Pharmaceuticals Announces Results From Phase 1b Trial Of Next Generation Capecitabine For Stage III/IV GI Cancer, Establishing Maximum Tolerated Dose And Recommended Phase 2 Dose Range
Portfolio Pulse from Benzinga Newsdesk
Processa Pharmaceuticals announced positive results from its Phase 1b trial of a next-generation capecitabine for Stage III/IV GI cancer. The trial established the maximum tolerated dose and recommended Phase 2 dose range, with 66.7% of patients achieving progression-free survival ranging from 5 to 11 months.
June 11, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Processa Pharmaceuticals announced positive results from its Phase 1b trial of a next-generation capecitabine for Stage III/IV GI cancer. The trial established the maximum tolerated dose and recommended Phase 2 dose range, with 66.7% of patients achieving progression-free survival ranging from 5 to 11 months.
The positive results from the Phase 1b trial indicate a promising future for Processa Pharmaceuticals' next-generation capecitabine, potentially leading to successful Phase 2 trials and increased investor confidence. This could result in a short-term positive impact on PCSA's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100